Recruitment

Recruitment Status
Unknown status

Inclusion Criterias

Patients > 18 years of age
Since this study does not involve treatments that have potential teratogenicity, and in general avoidance of antimicrobial treatment during pregnancy is advised (metronidazole is pregnancy category C), women of child-bearing age may be included in the study.
The patient has been treated with appropriate antimicrobial therapy for CDI.
...
Patients > 18 years of age
Since this study does not involve treatments that have potential teratogenicity, and in general avoidance of antimicrobial treatment during pregnancy is advised (metronidazole is pregnancy category C), women of child-bearing age may be included in the study.
The patient has been treated with appropriate antimicrobial therapy for CDI.
The patient has documented relapse/recurrence of infection as demonstrated by positive stool culture, or cytotoxin assay, or PCR toxin assay.

Summary

Conditions
Clostridium Difficile
Type
Interventional
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criterias

Patients > 18 years of age
Since this study does not involve treatments that have potential teratogenicity, and in general avoidance of antimicrobial treatment during pregnancy is advised (metronidazole is pregnancy category C), women of child-bearing age may be included in the study.
The patient has been treated with appropriate antimicrobial therapy for CDI.
...
Patients > 18 years of age
Since this study does not involve treatments that have potential teratogenicity, and in general avoidance of antimicrobial treatment during pregnancy is advised (metronidazole is pregnancy category C), women of child-bearing age may be included in the study.
The patient has been treated with appropriate antimicrobial therapy for CDI.
The patient has documented relapse/recurrence of infection as demonstrated by positive stool culture, or cytotoxin assay, or PCR toxin assay.

Locations

Peoria, Illinois, 61637
Peoria, Illinois, 61637

Tracking Information

NCT #
NCT01973465
Collaborators
Not Provided
Investigators
  • Principal Investigator: John J Farrell, M.D. OSF Healthcare System
  • John J Farrell, M.D. OSF Healthcare System